Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial
Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒
FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables Initial U.S. Clinical Trial
Amgen Collaboration Continues to Progress; Company Evaluating Additional Molecules, Including GLP-2, in Multiple Pre-clinical Studies
Company Strengthened Balance Sheet and Now Funded into the Second Quarter of 2022
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET